A preliminary trial of beta-carotene in subjects infected with the human immunodeficiency virus
beta-Carotene is a nontoxic carotenoid with immunomodulating properties in animals and humans. Based on our observations in normal immunocompetent subjects, we studied the effects of this compound in 11 patients infected with the human immunodeficiency virus (HIV). Each subject received 60 mg of bet...
Gespeichert in:
| Veröffentlicht in: | The Journal of nutrition 1992-03, Vol.122 (3S), p.728-732 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 732 |
|---|---|
| container_issue | 3S |
| container_start_page | 728 |
| container_title | The Journal of nutrition |
| container_volume | 122 |
| creator | Garewal, H.S. (Tucson VA Medical Center, Tucson, AZ) Ampel, N.M Watson, R.R Prabhala, R.H Dols, C.L |
| description | beta-Carotene is a nontoxic carotenoid with immunomodulating properties in animals and humans. Based on our observations in normal immunocompetent subjects, we studied the effects of this compound in 11 patients infected with the human immunodeficiency virus (HIV). Each subject received 60 mg of beta-carotene daily for 4 mo. Clinical and laboratory studies were obtained at baseline, every month while on treatment and for 2 mo after treatment. Increases in the percent of cells expressing Leu 11 (natural killer cells), Ia antigen and transferrin receptor (activated lymphocytes) were observed after 3 mo of treatment with beta-carotene and diminished thereafter. Major changes were not seen in total lymphocyte count or in the percent of cells expressing CD11, CD8 or CD4 antigens. No clinical toxicity was observed. These data suggest that beta-carotene can modulate certain immune markers in HIV-infected subjects. Further study of this compound in HIV infection may be warranted |
| doi_str_mv | 10.1093/jn/122.suppl_3.728 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_197410874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1446366601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-f1797229ab8129333412be42cfe7c72375066e9a552350c35f79f9d5129364ed3</originalsourceid><addsrcrecordid>eNpFkE1P3DAQQK0KBFvaP4CEZKFes3j8EcdHhCithNQDcLYcx-46SpzUTor493i1KzjNaObNjOYhdAlkC0Sxmz7eAKXbvM7zoNlW0uYL2oDgUNVAyAnaEEJpxaCuz9HXnHtCCHDVnKEzYFyW-gbpWzwnN4QxRJPe8JKCGfDkcesWU1mTpsVFh0PEeW17Z5dccl-i6_BrWHZ42Tm8W0cTcRjHNU6d88EGF-0b_h_Smr-hU2-G7L4f4wV6-Xn_fPerevzz8Pvu9rGyHORSeZBKUqpM2wBVjDEOtHWcWu-klZRJQeraKSMEZYJYJrxUXnViD9fcdewCXR_2zmn6t7q86H5aUywnNSjJgTSSF4geIJumnJPzek5hLH9rIHpvVPdRF6P6aFQXo2Xo6rh5bUfXfY4cFJb-j2PfZGsGn0y0IX9gAupG8D12ecC8mbT5mwry8qRAEsYoewfHiohb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>197410874</pqid></control><display><type>article</type><title>A preliminary trial of beta-carotene in subjects infected with the human immunodeficiency virus</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Garewal, H.S. (Tucson VA Medical Center, Tucson, AZ) ; Ampel, N.M ; Watson, R.R ; Prabhala, R.H ; Dols, C.L</creator><creatorcontrib>Garewal, H.S. (Tucson VA Medical Center, Tucson, AZ) ; Ampel, N.M ; Watson, R.R ; Prabhala, R.H ; Dols, C.L</creatorcontrib><description>beta-Carotene is a nontoxic carotenoid with immunomodulating properties in animals and humans. Based on our observations in normal immunocompetent subjects, we studied the effects of this compound in 11 patients infected with the human immunodeficiency virus (HIV). Each subject received 60 mg of beta-carotene daily for 4 mo. Clinical and laboratory studies were obtained at baseline, every month while on treatment and for 2 mo after treatment. Increases in the percent of cells expressing Leu 11 (natural killer cells), Ia antigen and transferrin receptor (activated lymphocytes) were observed after 3 mo of treatment with beta-carotene and diminished thereafter. Major changes were not seen in total lymphocyte count or in the percent of cells expressing CD11, CD8 or CD4 antigens. No clinical toxicity was observed. These data suggest that beta-carotene can modulate certain immune markers in HIV-infected subjects. Further study of this compound in HIV infection may be warranted</description><identifier>ISSN: 0022-3166</identifier><identifier>EISSN: 1541-6100</identifier><identifier>DOI: 10.1093/jn/122.suppl_3.728</identifier><identifier>PMID: 1347316</identifier><identifier>CODEN: JONUAI</identifier><language>eng</language><publisher>Bethesda, MD: American Society for Nutritional Sciences</publisher><subject>Adult ; ANTIGENE ; ANTIGENOS ; beta Carotene ; Biological and medical sciences ; CAROTENOIDE ; CAROTENOIDES ; Carotenoids - therapeutic use ; CD4-Positive T-Lymphocytes - immunology ; CD4-Positive T-Lymphocytes - pathology ; Cells ; Drug Evaluation ; GENERO HUMANO ; GENRE HUMAIN ; HERPETOVIRIDAE ; HIV ; HIV Infections - drug therapy ; HIV Infections - immunology ; HOMBRES ; HOMME ; Human immunodeficiency virus ; Humans ; Immune system ; IMMUNITE CELLULAIRE ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; INMUNIDAD CELULAR ; Leukocyte Count ; LINFOCITOS ; LYMPHOCYTE ; Lymphocyte Activation ; Lymphocytes ; Lymphocytes - immunology ; Lymphocytes - pathology ; Male ; Medical sciences ; Middle Aged ; ORGANISME INDICATEUR ; ORGANISMOS INDICADORES ; Skin Tests ; VITAMINAS ; VITAMINE</subject><ispartof>The Journal of nutrition, 1992-03, Vol.122 (3S), p.728-732</ispartof><rights>1992 INIST-CNRS</rights><rights>Copyright American Institute of Nutrition Mar 1992</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-f1797229ab8129333412be42cfe7c72375066e9a552350c35f79f9d5129364ed3</citedby><cites>FETCH-LOGICAL-c417t-f1797229ab8129333412be42cfe7c72375066e9a552350c35f79f9d5129364ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5168546$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1347316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garewal, H.S. (Tucson VA Medical Center, Tucson, AZ)</creatorcontrib><creatorcontrib>Ampel, N.M</creatorcontrib><creatorcontrib>Watson, R.R</creatorcontrib><creatorcontrib>Prabhala, R.H</creatorcontrib><creatorcontrib>Dols, C.L</creatorcontrib><title>A preliminary trial of beta-carotene in subjects infected with the human immunodeficiency virus</title><title>The Journal of nutrition</title><addtitle>J Nutr</addtitle><description>beta-Carotene is a nontoxic carotenoid with immunomodulating properties in animals and humans. Based on our observations in normal immunocompetent subjects, we studied the effects of this compound in 11 patients infected with the human immunodeficiency virus (HIV). Each subject received 60 mg of beta-carotene daily for 4 mo. Clinical and laboratory studies were obtained at baseline, every month while on treatment and for 2 mo after treatment. Increases in the percent of cells expressing Leu 11 (natural killer cells), Ia antigen and transferrin receptor (activated lymphocytes) were observed after 3 mo of treatment with beta-carotene and diminished thereafter. Major changes were not seen in total lymphocyte count or in the percent of cells expressing CD11, CD8 or CD4 antigens. No clinical toxicity was observed. These data suggest that beta-carotene can modulate certain immune markers in HIV-infected subjects. Further study of this compound in HIV infection may be warranted</description><subject>Adult</subject><subject>ANTIGENE</subject><subject>ANTIGENOS</subject><subject>beta Carotene</subject><subject>Biological and medical sciences</subject><subject>CAROTENOIDE</subject><subject>CAROTENOIDES</subject><subject>Carotenoids - therapeutic use</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD4-Positive T-Lymphocytes - pathology</subject><subject>Cells</subject><subject>Drug Evaluation</subject><subject>GENERO HUMANO</subject><subject>GENRE HUMAIN</subject><subject>HERPETOVIRIDAE</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HOMBRES</subject><subject>HOMME</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immune system</subject><subject>IMMUNITE CELLULAIRE</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>INMUNIDAD CELULAR</subject><subject>Leukocyte Count</subject><subject>LINFOCITOS</subject><subject>LYMPHOCYTE</subject><subject>Lymphocyte Activation</subject><subject>Lymphocytes</subject><subject>Lymphocytes - immunology</subject><subject>Lymphocytes - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>ORGANISME INDICATEUR</subject><subject>ORGANISMOS INDICADORES</subject><subject>Skin Tests</subject><subject>VITAMINAS</subject><subject>VITAMINE</subject><issn>0022-3166</issn><issn>1541-6100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1P3DAQQK0KBFvaP4CEZKFes3j8EcdHhCithNQDcLYcx-46SpzUTor493i1KzjNaObNjOYhdAlkC0Sxmz7eAKXbvM7zoNlW0uYL2oDgUNVAyAnaEEJpxaCuz9HXnHtCCHDVnKEzYFyW-gbpWzwnN4QxRJPe8JKCGfDkcesWU1mTpsVFh0PEeW17Z5dccl-i6_BrWHZ42Tm8W0cTcRjHNU6d88EGF-0b_h_Smr-hU2-G7L4f4wV6-Xn_fPerevzz8Pvu9rGyHORSeZBKUqpM2wBVjDEOtHWcWu-klZRJQeraKSMEZYJYJrxUXnViD9fcdewCXR_2zmn6t7q86H5aUywnNSjJgTSSF4geIJumnJPzek5hLH9rIHpvVPdRF6P6aFQXo2Xo6rh5bUfXfY4cFJb-j2PfZGsGn0y0IX9gAupG8D12ecC8mbT5mwry8qRAEsYoewfHiohb</recordid><startdate>19920301</startdate><enddate>19920301</enddate><creator>Garewal, H.S. (Tucson VA Medical Center, Tucson, AZ)</creator><creator>Ampel, N.M</creator><creator>Watson, R.R</creator><creator>Prabhala, R.H</creator><creator>Dols, C.L</creator><general>American Society for Nutritional Sciences</general><general>American Institute of Nutrition</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>19920301</creationdate><title>A preliminary trial of beta-carotene in subjects infected with the human immunodeficiency virus</title><author>Garewal, H.S. (Tucson VA Medical Center, Tucson, AZ) ; Ampel, N.M ; Watson, R.R ; Prabhala, R.H ; Dols, C.L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-f1797229ab8129333412be42cfe7c72375066e9a552350c35f79f9d5129364ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>ANTIGENE</topic><topic>ANTIGENOS</topic><topic>beta Carotene</topic><topic>Biological and medical sciences</topic><topic>CAROTENOIDE</topic><topic>CAROTENOIDES</topic><topic>Carotenoids - therapeutic use</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD4-Positive T-Lymphocytes - pathology</topic><topic>Cells</topic><topic>Drug Evaluation</topic><topic>GENERO HUMANO</topic><topic>GENRE HUMAIN</topic><topic>HERPETOVIRIDAE</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HOMBRES</topic><topic>HOMME</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immune system</topic><topic>IMMUNITE CELLULAIRE</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>INMUNIDAD CELULAR</topic><topic>Leukocyte Count</topic><topic>LINFOCITOS</topic><topic>LYMPHOCYTE</topic><topic>Lymphocyte Activation</topic><topic>Lymphocytes</topic><topic>Lymphocytes - immunology</topic><topic>Lymphocytes - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>ORGANISME INDICATEUR</topic><topic>ORGANISMOS INDICADORES</topic><topic>Skin Tests</topic><topic>VITAMINAS</topic><topic>VITAMINE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garewal, H.S. (Tucson VA Medical Center, Tucson, AZ)</creatorcontrib><creatorcontrib>Ampel, N.M</creatorcontrib><creatorcontrib>Watson, R.R</creatorcontrib><creatorcontrib>Prabhala, R.H</creatorcontrib><creatorcontrib>Dols, C.L</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>The Journal of nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garewal, H.S. (Tucson VA Medical Center, Tucson, AZ)</au><au>Ampel, N.M</au><au>Watson, R.R</au><au>Prabhala, R.H</au><au>Dols, C.L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A preliminary trial of beta-carotene in subjects infected with the human immunodeficiency virus</atitle><jtitle>The Journal of nutrition</jtitle><addtitle>J Nutr</addtitle><date>1992-03-01</date><risdate>1992</risdate><volume>122</volume><issue>3S</issue><spage>728</spage><epage>732</epage><pages>728-732</pages><issn>0022-3166</issn><eissn>1541-6100</eissn><coden>JONUAI</coden><abstract>beta-Carotene is a nontoxic carotenoid with immunomodulating properties in animals and humans. Based on our observations in normal immunocompetent subjects, we studied the effects of this compound in 11 patients infected with the human immunodeficiency virus (HIV). Each subject received 60 mg of beta-carotene daily for 4 mo. Clinical and laboratory studies were obtained at baseline, every month while on treatment and for 2 mo after treatment. Increases in the percent of cells expressing Leu 11 (natural killer cells), Ia antigen and transferrin receptor (activated lymphocytes) were observed after 3 mo of treatment with beta-carotene and diminished thereafter. Major changes were not seen in total lymphocyte count or in the percent of cells expressing CD11, CD8 or CD4 antigens. No clinical toxicity was observed. These data suggest that beta-carotene can modulate certain immune markers in HIV-infected subjects. Further study of this compound in HIV infection may be warranted</abstract><cop>Bethesda, MD</cop><pub>American Society for Nutritional Sciences</pub><pmid>1347316</pmid><doi>10.1093/jn/122.suppl_3.728</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3166 |
| ispartof | The Journal of nutrition, 1992-03, Vol.122 (3S), p.728-732 |
| issn | 0022-3166 1541-6100 |
| language | eng |
| recordid | cdi_proquest_journals_197410874 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult ANTIGENE ANTIGENOS beta Carotene Biological and medical sciences CAROTENOIDE CAROTENOIDES Carotenoids - therapeutic use CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - pathology Cells Drug Evaluation GENERO HUMANO GENRE HUMAIN HERPETOVIRIDAE HIV HIV Infections - drug therapy HIV Infections - immunology HOMBRES HOMME Human immunodeficiency virus Humans Immune system IMMUNITE CELLULAIRE Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology INMUNIDAD CELULAR Leukocyte Count LINFOCITOS LYMPHOCYTE Lymphocyte Activation Lymphocytes Lymphocytes - immunology Lymphocytes - pathology Male Medical sciences Middle Aged ORGANISME INDICATEUR ORGANISMOS INDICADORES Skin Tests VITAMINAS VITAMINE |
| title | A preliminary trial of beta-carotene in subjects infected with the human immunodeficiency virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T14%3A15%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20preliminary%20trial%20of%20beta-carotene%20in%20subjects%20infected%20with%20the%20human%20immunodeficiency%20virus&rft.jtitle=The%20Journal%20of%20nutrition&rft.au=Garewal,%20H.S.%20(Tucson%20VA%20Medical%20Center,%20Tucson,%20AZ)&rft.date=1992-03-01&rft.volume=122&rft.issue=3S&rft.spage=728&rft.epage=732&rft.pages=728-732&rft.issn=0022-3166&rft.eissn=1541-6100&rft.coden=JONUAI&rft_id=info:doi/10.1093/jn/122.suppl_3.728&rft_dat=%3Cproquest_cross%3E1446366601%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=197410874&rft_id=info:pmid/1347316&rfr_iscdi=true |